Floatz Rating
C39/100
Confidence
Indicative
Sponsor
West China Hospital
Modality
nucleic_acid
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07583914CT.gov Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ncp-Cd47 Sirna Intratumorally (this asset) | West China Hospital | P1 | C · 39 |
| Nepenthe | Instituto Nacional de Cancer, Brazil | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P3 | BB |
| Lidocaine | Instituto Nacional de Cancer, Brazil | P3 | BB |
| Carboplatin | Rapa Therapeutics LLC | P3 | BB |
| Cyclophosphamide | Zelluna Immunotherapy AS | P3 | BB |
| Nivestim | University of Colorado, Denver | P2 | BB |
| Cetuximab | Pfizer | P3 | BB |
| Pembrolizumab | Thomas Jefferson University | P3 | BB |
+42 more in the Head And Neck Cancer cohort
Other indications for Ncp-Cd47 Sirna Intratumorally
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ncp-Cd47 Sirna Intratumorally in Head And Neck Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ncp-cd47-sirna-intratumorally-head-and-neck-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →